Neuropilin 1 (NRP1), a transmembrane nontyrosine-kinase glycoprotein in the neuropilin family, plays an important role in angiogenesis and vasculogenesis [1–3]. Altered expression of NRP1 promotes tumor proliferation, angiogenesis, and metastasis by triggering vascular endothelial growth factor (VEGF) and other pathways [3, 4]. The abnormal expression of NRP1 has been found in various malignant tumors, including chest tumors, abdominal tumors, and nervous system tumors [4]. In gastric cancer (GC), high expression of NRP1 is closely related to the development of tumor progression and associated with poor overall survival [5]. Furthermore, recent report indicated that anti-NRP-1 mAb might be a novel therapeutic approach in the treatment of gastric cancer [6].

For over a decade, a number of studies have examined the expression of NRP1 protein in gastric cancer and analyzed the relationship between the abnormal expression of NRP1 protein and the clinicopathological characteristics of gastric cancer. For instance, Peng [7] reported no difference of NRP1 expression was found between GC patients with and without lymph node metastasis group. Conversely, Yang et al. [8] demonstrated that the positive expression of NRP1 was correlated with lymph node metastasis in GC patients. In addition, Zhang et al. [9] demonstrated no correlation between NRP1 expression and histological differentiation in GC patients. However, Fan et al. [10] concluded that the high
expression of NRP1 was associated with differentiation in GC patients. Altogether, the correlation between the expression of NRP1 and the clinicopathological characteristics of GC remains controversial.

To overcome the limited power of individual study with inconsistent results, we used quantitative meta-analysis to evaluate the associations between NRP1 protein expression and the clinicopathological features in gastric cancer.

2. Materials and Methods

2.1. Literature Search Strategy. Databases including CNKI, Wanfang, Chongqing VIP, Web of Science, and PubMed were searched for relevant studies conducted on human subject until September 2019. There was no restriction for language. Relevant studies were identified in PubMed database by using the following terms: “(Neuropilin* or NRP*) and (gastric OR stomach) and (cancer or carcinoma or neoplasm or tumor)”. Searching strategies in other included databases were adjusted based on these keywords.

2.2. Inclusion and Exclusion Criteria. All articles that examined the relationship between the expression of NRP1 and clinicopathological variables of gastric cancer were extracted. The following inclusion criteria were applied for selection: (1) patients with gastric cancer were diagnosed histopathologically; (2) expression of NRP1 protein was measured in patients with gastric cancer by immunohistochemistry, and (3) reported the relationship between the expression of NRP1 and clinicopathological characteristics of patients.

Exclusion criteria were as follows: (1) no sufficient data to calculate the odds ratio (OR) of the NRP1 expression with clinicopathological features; (2) articles of letters, reviews, case reports, and conference abstracts with no original data. If the same research group published data on the same group of patients in more than one journal, the most complete study was selected for the present meta-analysis.

2.3. Data Extraction and Quality Assessment. Two investigators (Hui Cao and Zhong Xu) assessed the studies according to inclusion and exclusion criteria. Disagreements were resolved by discussion. Senior reviewers (Banjun Bai) reviewed the final results before next step. The quality of the included studies was evaluated by the Newcastle-Ottawa Scale (NOS) [11, 12]. The following information was recorded from the included studies: first author, publication year, country, number of gastric cancer cases, and NRP1 expression in gastric cancer with clinicopathological features.

2.4. Statistical Analysis. Association of NRP1 expression and correlation with clinicopathological features in gastric cancer was estimated by odds ratios (ORs) with 95% confidence intervals (95% CIs), and $P < 0.05$ was considered representative of statistically significant publication bias. Statistical analyses for the meta-analysis were performed using the software Stata12.0 (Stata Corporation, College Station, Texas).

This study uses the method of our previous publication, and the method description partly reproduces the wording [15].

3. Results

3.1. Study Characteristics. A total of 665 records were identified from online databases for selection. 566 records were included for further screening after removing duplication. The flow chart summarizes the complete literature selection process as shown in Figure 1. Finally, we enrolled 12 eligible studies containing 1,225 gastric cancer patients into our meta-analysis [7–10, 16–23]. Among these studies, 10 were reported in Chinese and 2 in English. All these studies were conducted in China. Characteristics of the included studies in this meta-analysis are summarized in Table 1. The quality scores indicate all of included literatures are high-quality.

3.2. Meta-Analysis Results

3.2.1. Gender. All included studies reported the relationship between NRP1 expression and gender. The fixed-effects model was used to pool these researches as no statistical heterogeneity was observed between studies ($P_{Q-test} > 0.1$, $I^2 < 50\%$). The pooled results indicated that there was no significant relationship between NRP1 expression and gender (male versus female: $OR = 0.776$, 95% CI = 0.601 – 1.001, $P = 0.051$).

3.2.2. Age. Nine studies [8–10, 16–21] reported the relationship between NRP1 expression and age (<60 versus ≥60). The fixed-effects model was used to pool these researches as no statistical heterogeneity was observed between studies. The pooled results indicated that there was no significant relationship between NRP1 expression and age (OR = 0.983, 95% CI = 0.750 – 1.288, $P = 0.900$).

3.2.3. Stage. Three studies assessed [16, 18, 19] the relationship between NRP1 expression and stage. The fixed-effects model was used to pool these researches as no statistical heterogeneity was observed between studies. The pooled results indicated that there was a significant association between NRP1 expression and the tumor stage of gastric cancer (early stage versus advanced stage: $OR = 0.128$, 95% CI = 0.059 – 0.277, $P < 0.001$).

3.2.4. Tumor Size. Seven studies assessed [8–10, 16–19] the relationship between NRP1 expression and tumor size. The fixed-effects model was used to pool these researches as no statistical heterogeneity was observed between studies (Figure 2). The pooled results indicated that there was a significant association between NRP1 expression and the tumor size of gastric cancer (tumor size less than 5 cm versus more than 5 cm: $OR = 0.443$, 95% CI = 0.310 – 0.632, $P < 0.001$).
Records identified through database searching \((n = 665)\)

Records after duplicates removed \((n = 566)\)

Records screened \((n = 566)\)

Records excluded \((n = 520)\)

Full-text articles assessed for eligibility \((n = 46)\)

Full-text articles excluded
3 duplicate
12 no usable data
18 not NRP1 and GC
1 review \((n = 34)\)

Studies included in qualitative synthesis \((n = 12)\)

Studies included in quantitative synthesis (meta-analysis) \((n = 12)\)

**Figure 1**: Flow chart of study inclusion and exclusion.

**Table 1**: Characteristics and quality evaluation of included studies.

| First author | Year | Language | Country | GC number | Gender (male/female) | NOS score |
|--------------|------|----------|---------|-----------|----------------------|-----------|
| Wei S        | 2006 | Chinese  | China   | 60        | 43/17                | 8         |
| Peng Y       | 2011 | Chinese  | China   | 63        | 42/21                | 7         |
| Hu X         | 2013 | Chinese  | China   | 62        | 50/12                | 6         |
| Liu Y        | 2014 | Chinese  | China   | 65        | 42/23                | 8         |
| Yang J       | 2015 | Chinese  | China   | 72        | 57/15                | 7         |
| Yang S       | 2015 | Chinese  | China   | 168       | 101/67               | 8         |
| Li L         | 2016 | English  | China   | 141       | 87/54                | 7         |
| Zhang Y      | 2016 | Chinese  | China   | 60        | 35/25                | 7         |
| Zhang L      | 2017 | English  | China   | 203       | 133/70               | 7         |
| Fan D        | 2018 | Chinese  | China   | 109       | 68/41                | 7         |
| Shi X        | 2018 | Chinese  | China   | 94        | 54/40                | 7         |
| Nie N        | 2019 | Chinese  | China   | 128       | 79/49                | 7         |
Figure 2: Forest plot about the association between neuropilin 1 expression and tumor size in gastric cancer (less than 5 cm versus more than 5 cm).

Figure 3: Forest plot about the association between neuropilin 1 expression and TNM stages in gastric cancer (stage I-II group versus stage III-IV group).
**Figure 4:** Forest plot about the association between neuropilin 1 expression and differentiation in gastric cancer (well to medium differentiation group versus poor differentiation group).

**Figure 5:** Forest plot about the association between neuropilin 1 expression and metastasis of lymph node in gastric cancer (non-lymph node metastasis group versus lymph node metastasis group).
3.2.5. Laurèn’s Classification. Two studies [8, 21] assessed the relationship between NRP1 expression and Laurèn’s classification. The fixed-effects model was used to pool the researches as no statistical heterogeneity was observed between studies. The results indicated that there was no significant relationship between NRP1 expression and Laurèn’s classification (Lauren diffuse type versus intestinal type: OR = 0.729, 95% CI = 0.445 – 1.193, P = 0.208).

3.2.6. pTNM Stages. Eleven studies [7–10, 16–21, 23] assessed the relationship between NRP1 expression and pTNM stages. The random-effects model was used to pool these researches as statistical heterogeneity was observed between studies (P_Q-test < 0.1, I² > 50%). As shown in Figure 3, NRP1 expression rate in patients with stages I and II gastric cancer was much lower than those with III and IV gastric cancer (OR = 0.736, 95% CI = 0.589 – 0.919, P = 0.007).

3.2.7. Differentiation. All included studies assessed the relationship between the NRP1 expression and histologic type. The random-effects model was used to pool these researches as statistical heterogeneity was observed between studies (Figure 4). The results indicated that well/moderate differentiation patients of gastric cancer had a much lower NRP1
expression rate versus poor differentiation group (OR = 0.735, 95% CI = 0.632 – 0.854, P ≤ 0.001).

3.2.8. Metastasis of Lymph Node. Ten studies [7–10, 16–19, 21, 22] assessed the relationship between the NRP1 expression and metastasis of lymph node. The random-effects model was used to pool these researches as statistical heterogeneity was observed between studies. As shown in Figure 5, NRP1 expression rate in patients without lymph node metastasis was much lower than those with lymph node metastasis (OR = 0.667, 95% CI = 0.522 – 0.854, P = 0.001).

3.3. Publication Bias. Begg’s funnel plot (Figure 6) and Egger’s publication bias plot (Figure 7) did not show any evidence of obvious asymmetry. The statistical test indicated no potential publication bias (P > 0.05).

4. Discussion

NRP1 is involved in the development of cardiovascular system and the pathogenesis of cancer with an important role in angiogenesis. Studies indicated that NRP1 is abnormally expressed in a variety of tumor cells, including gastric cancer. NRP1 can participate in tumor development and promote tumor metastasis by eliciting a range of intracellular signaling cascades [24, 25]. Published data have shown that the analysis of NRP1 expression levels could provide a predictive marker of clinical outcome and prognosis in gastric cancer [5, 21, 26, 27]. Also, it is an exciting and challenging endeavor to employ NRP1-inhibitory strategies for cancer treatment [6, 28]. Therefore, studies on the relationship of NRP1 expression and clinicopathological characteristics of GC by IHC emerged with inconclusive results from different publications.

To systematically investigate the relationship between the expression of NRP1 protein and clinicopathological features of gastric cancer, the present study screened the published literature regarding the expression of NRP1 in gastric cancer by immunohistochemistry, and pooled the available data by meta-analysis. A total of 12 studies including 1225 gastric cancer patients were included in the analysis. The results showed that the positive rate of NRP1 protein expression in gastric cancer was higher in those with tumor larger than 5 cm versus with tumor smaller than 5 cm, higher in those with stages III-IV than with stages I-II, higher in low differentiation than well/moderate differentiation, and higher in those with lymph node metastasis than without lymph node metastasis. There was no statistical significance association between the expression of NRP1 protein and gender, age, clinical stage, and Laurèn’s classification in gastric cancer.

The main disadvantages in our meta-analysis include (1) all the included studies are from China and ethnicity was not identified within each study; (2) the number of samples included in the study is limited; also, the focused of reports are various. For example, 7 studies provide relevant data for analysis about the comparison of tumor size, while only 2 items have relevant data about Laurèn’s classification; (3) in terms of detection methods, although all of them are measured by immunohistochemistry, it is inevitable some differences among different research groups and different operators, such as the source of antibodies, specific experimental, dilution concentration, result judgment criteria, and other factors. The above may also be the main reason for the heterogeneity between studies.

5. Conclusions

In conclusion, the current studies show that NRP1 protein expression in gastric cancer is related to tumor size, TNM stage, differentiation degree, and lymph node metastasis and has a higher positive rate in patients of tumor size over 5 cm, TNM stages III-IV, low differentiation, and with lymph node metastasis. The detection of NRP1 protein expression might be useful to determine the lymph node metastasis in patients with gastric cancer. Further studies with larger samples and different ethnicities are required to confirm an association between NRP1 protein expression and the clinicopathological features of gastric cancer.

Data Availability

The raw data supporting this meta-analysis are from previously reported studies, which have been cited. The processed data are included within the article. The full processed data in detail are also available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

BB and XZ designed the research study. CH and XZ performed the search, extracted the data, and drafted the manuscript. XZ and LY analyzed the data. All authors contributed to discussion and reviewed the manuscript.

Acknowledgments

This work was supported by Guizhou Provincial Science and Technology Foundation (grant number 2012-2235).

References

[1] C. Grandclément and C. Borg, “Neuropilins: a new target for cancer therapy,” *Cancers*, vol. 3, no. 2, pp. 1899–1928, 2011.
[2] T. Kawasaki, T. Kitsukawa, Y. Bekku et al., “A requirement for neuropilin-1 in embryonic vessel formation,” *Development*, vol. 126, no. 21, pp. 4895–4902, 1999.
[3] H. Oh, H. Takagi, A. Otani et al., “Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 1, pp. 383–388, 2002.
[4] S. Niland and J. A. Eble, “Neuropilins in the context of tumor vasculature,” *International Journal of Molecular Sciences*, vol. 20, no. 3, p. 639, 2019.
[5] G. Wang, B. Shi, Y. Fu et al., ”Hypomethylated gene NRP1 is co-expressed with PDGFRB and associated with poor overall survival in gastric cancer patients,” Biomedicine & Pharmacotherapy, vol. 111, pp. 1334–1341, 2019.

[6] Y. Ding, J. Zhou, S. Wang et al., ”Anti-neuropilin-1 monoclonal antibody suppresses the migration and invasion of human gastric cancer cells via Akt dephosphorylation,” Experimental and Therapeutic Medicine, vol. 16, no. 2, pp. 537–546, 2018.

[7] Y. Peng, The expression of NRP1 in gastric carcinomas and the experimental research about curbing the growth of the nude mice transplanted tumor, Chongqing Medical University, Chongqing, 2011.

[8] J. Yang, L. Zhang, M. Zheng, Q. Wang, X. U. Yuting, and H. Liu, ”Expression of VEGF, NRP1 and cancer stem cell marker CD44 in gastric carcinoma and their correlations,” Chinese Journal of Clinical and Experimental Pathology, vol. 31, no. 2, pp. 124–127, 2015.

[9] Y. Zhang, M. Zhao, R. Zhu, and Y. Gu, ”The impact of survivin, NRP1 in gastric cancer and its prognosis of gastric cancer,” China Modern Doctor, vol. 54, no. 25, pp. 8–11, 2016.

[10] D. Fan, C. Zhang, C. Yao, S. Sun, X. Li, and T. Yao, ”Expression of NRP-1 in gastric cancer tissue and its role,” Journal of Qiqihar Medical University, vol. 39, no. 6, pp. 625–628, 2018.

[11] G. Wells, B. Shea, D. O’Connell et al., ”The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses,” 2011, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

[12] L. Yao, M. Liu, Y. Huang et al., ”Metformin use and lung cancer risk in diabetic patients: a systematic review and meta-analysis,” Disease Markers, vol. 2019, Article ID 6230162, 9 pages, 2019.

[13] C. B. Begg and M. Mazumdar, ”Operating characteristics of a rank correlation test for publication bias,” Biometrics, vol. 50, no. 4, pp. 1088–1101, 1994.

[14] M. Egger, G. D. Smith, M. Schneider, and C. Minder, ”Bias in meta-analysis detected by a simple, graphical test,” BMJ, vol. 315, no. 7109, pp. 629–634, 1997.

[15] Z. Xu, L. Zhang, H. Cao, and B. Bai, ”MiR-146a rs2910164 G/C polymorphism and gastric cancer susceptibility: a meta-analysis,” BMC Medical Genetics, vol. 15, no. 1, p. 117, 2014.

[16] S. Wei, The expression of Neuropilin-1 in gastric carcinoma and its role in gastric carcinoma angiogenesis, Guangxi Medical University, Nanning, 2006.

[17] X. Hu, Y. Wang, G. Jin, X. Sun, C. Lu, and J. Wang, ”Correlation of neuropilin-1 expression with tumor progression and angiogenesis in human gastric carcinoma,” Zhejiang Medical Journal, vol. 5, pp. 347–350, 2013.

[18] Y. Liu, Correlation analysis between expression of neuropilins to tumor angiogenesis/lymphangiogenesis and vascular/lymphatic metastasis in gastric cancer, Hebei United University, Tangshan, 2014.

[19] S. Yang, Expression of NRP1 in gastric cancer and its correlations with clinicopathological factors and clinical prognosis, North China University of Science and Technology, Tangshan, 2015.

[20] L. Li, X. Jiang, Q. Zhang et al., ”Neuropilin-1 is associated with clinicopathology of gastric cancer and contributes to cell proliferation and migration as multifunctional co-receptors,” Journal of Experimental & Clinical Cancer Research, vol. 35, no. 1, p. 16, 2016.

[21] L. Zhang, Y. Xing, Q. Gao, X. Sun, D. Zhang, and G. Cao, ”Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells,” Biomedicine & Pharmacotherapy, vol. 93, pp. 1136–1143, 2017.

[22] X. Shi, X. Zhang, J. Zhu, W. Di, and L. Tian, ”Expression and significance of NRP1 and NRP2 in gastric adenocarcinoma,” Chinese Journal of Gerontology, vol. 38, no. 1, pp. 122–124, 2018.

[23] N. Nie, X. Wu, H. Yu, B. Ning, and B. Liu, ”Expression of NRP1 and NRP2 in gastric carcinoma and its correlation with clinicopathological features,” Chinese Journal of the Frontiers of Medical Science, vol. 11, no. 5, pp. 115–118, 2019.

[24] C. Hu and X. Jiang, ”Role of NRP-1 in VEGF-VEGFR2-independent tumorigenesis,” Targeted Oncology, vol. 11, no. 4, pp. 501–505, 2016.

[25] A. Plein, A. Fantin, and C. Ruhrberg, ”Neuropilin regulation of angiogenesis, arteriogenesis, and vascular permeability,” Microcirculation, vol. 21, no. 4, pp. 315–323, 2014.

[26] E. Van Cutsem, S. de Haas, Y.-K. Kang et al., ”Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial,” Journal of Clinical Oncology, vol. 30, no. 17, pp. 2119–2127, 2012.

[27] W. H. Yang, Z. Y. Lai, Y. Li et al., ”Immune signature profiling identified prognostic factors for gastric cancer,” Chinese Journal of Cancer Research, vol. 31, no. 3, pp. 463–470, 2019.

[28] Y. Huang, X. Li, H. Sha et al., ”Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy,” Oncology Reports, vol. 37, no. 4, pp. 2063–2070, 2017.